Healthcare / Drug Manufacturers - Specialty & GenericBSE
$1.21
+0.03 (+2.54%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-29.6M · quality 67.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$670M
P/E
121.0x
↑EV/EBITDA
23.1x
↑ROE
2.4%
↑Gross Margin
8.1%
↓Debt/Equity
0.53
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+76.9%
FCF CAGR
—
FCF margin
-12.9%
FCF / Net income
-11.28x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.40B · net income $16.0M · FCF $-180.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.40B | $1.40B | $337.2M | $304.1M | $252.8M |
| Net Income | $16.0M | $16.0M | $15.9M | $-1.7M | $11.2M |
| EBITDA | $43.8M | $43.8M | $34.6M | $7.0M | $3.6M |
| EPS | — | — | 0.03 | -0.01 | 0.02 |
| Gross Margin | 8.1% | 8.1% | 8.8% | 20.3% | 7.5% |
| Operating Margin | -0.7% | -0.7% | -1.2% | 1.4% | 0.3% |
| Net Margin | 1.1% | 1.1% | 4.7% | -0.6% | 4.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.53 | 0.53 | 0.08 | 0.06 | 0.20 |
| Current Ratio | 1.71 | 1.71 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-180.8M | $-180.8M | $-27.5M | $-29.6M | $-30.8M |
| Returns | |||||
| ROE | 2.4% | 2.4% | 2.4% | -0.3% | 7.3% |
| Valuation | |||||
| P/E | 121.00 | 121.00 | 66.33 | — | — |
| EV/EBITDA | 23.06 | 23.06 | 31.76 | — | — |
| P/B | 1.01 | 1.01 | 1.61 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 315.0% | 315.0% | 10.9% | 20.3% | — |
| EPS Growth | — | — | 599.6% | -125.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-44.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.03 → n/d
Residual
-44.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.